CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 93 enrolled
Drug / intervention
Crystalens AO +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01225952
NCT01225952Phase 4Completed
CompareCT.gov

A Three Arm Prospective Clinical Evaluation of Three FDA-approved Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction

Bausch & Lomb Incorporated·interventional·Posted Oct 21, 2010·Updated Jan 18, 2013

In Brief

A Phase 4 clinical trial evaluating Crystalens AO, ReSTOR 3.0, and 1 other intervention for Cataract. Completed, enrolled 93 participants across 1 site.

Detailed Summary

The objective of this study is to compare the contrast sensitivity, high and low contrast visual acuity (VA), glare meter outcomes, and subject satisfaction with three different FDA-approved intraocular lenses (IOLs) designed to improve distance, intermediate, and near vision following lens extraction in adults at least 40 years of age.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesPhilippines
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 21, 2010
Enrollment StartJul 1, 2010
Primary CompletionJun 1, 2011
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.7 years ago

Interventions

Crystalens AOdevice

Bausch \& Lomb model silicone multi-piece accommodating IOL.

ReSTOR 3.0device

An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.

AMO Tecnis Multifocaldevice

The Tecnis Multifocal foldable hydrophobic acrylic IOL, Model ZMA00 (Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL.